Alpha Teknova, Inc.: directors' dealings · United States · SEC (Form 4)

About Alpha Teknova, Inc.

Alpha Teknova, Inc. (ticker: TKNO) is a U.S.-listed company trading on Nasdaq in the United States. From an international equity perspective, TKNO is best understood as a life-science tools and consumables business rather than a drug developer. The company produces critical reagents used in the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, with exposure to research-grade and GMP-oriented demand across cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Its offering is therefore tied to the infrastructure of modern biotech, where reliable inputs and fast turnaround can be strategically important.([ir.teknova.com](https://ir.teknova.com/)) Teknova traces its roots to 1996, and the company later became Alpha Teknova, Inc. through a 2019 merger. That history matters because it reflects a long operating record in specialized reagents and a gradual shift toward a broader, more regulated product mix. Management says the company serves more than 3,000 customers across the life-sciences continuum, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. For investors, that customer base suggests diversified end-market exposure, though still within the same biotech ecosystem.([sec.gov](https://www.sec.gov/Archives/edgar/data/1850902/000185090226000002/tkno-20251231.htm)) The business is organized around two primary product categories: Lab Essentials and Clinical Solutions. Teknova’s main product types are pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. These products are used in early research, process development, and, increasingly, in more clinically relevant workflows. A key part of the company’s competitive position is its ability to offer both standard and highly customized formulations, which can support customer retention and pricing power in specialized applications.([sec.gov](https://www.sec.gov/Archives/edgar/data/1850902/000185090226000002/tkno-20251231.htm)) Operationally, Alpha Teknova manufactures at its Hollister, California headquarters, where it also stores raw materials, components, and finished goods. This vertically integrated setup supports control over quality and delivery, but it also concentrates manufacturing risk in a single location. In its latest annual reporting and earnings materials, the company emphasized improving execution and commercial expansion. For full-year 2025, revenue reached $40.5 million, up 7% year over year, with Clinical Solutions revenue growing faster than Lab Essentials. The company also highlighted improving gross margin and cash usage trends, and it guided to 2026 revenue of $42 million to $44 million.([sec.gov](https://www.sec.gov/Archives/edgar/data/1850902/000185090226000002/tkno-20251231.htm)) From a market-positioning standpoint, TKNO competes in a niche but essential segment of the biotech supply chain. It is not a broad-line lab supplier; instead, it focuses on value-added reagents and custom formulations where technical consistency, speed, and flexibility matter. That makes the stock interesting for investors seeking small-cap exposure to the life-science enabling layer. Recent company commentary suggests management is investing in commercial capabilities with the longer-term goal of reaching adjusted EBITDA profitability by the end of 2027, which frames the current story as a combination of revenue expansion and operating leverage.([ir.teknova.com](https://ir.teknova.com/static-files/b625bbb6-9160-4450-98e2-06e7f688e30f))